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Isolated lesions in the splenium of the corpus callosum 
(ILSCC) are an uncommon radiographic entity with an esti-
mated prevalence between 0.6% and 3.0%.1,2 ILSCCs are 
most commonly associated with a clinical presentation of 
delirium and have a broad differential diagnosis.2 With 
regard to neuroleptic malignant syndrome (NMS), recent lit-
erature has suggested a disease spectrum model with empha-
sis on identifying prodromal and atypical NMS variants in 
order to improve disease outcomes.3-5 Considering the esti-
mated incidence of NMS is between 0.01% and 0.02%, the 
co-occurrence of ILSCC and NMS is either exceedingly rare 
or an underrecognized clinical phenomenon.6 At the time of 
writing, only 7 publications exist documenting ILSCC in the 
context of NMS, the first of which was published in 2009.7-13 
In this report, we are the first to describe a case of atypical 
NMS presenting with an ILSCC. We are also the first to pub-
lish a case report to postulate a possible pathophysiological 
relationship between the development of ILSCC and NMS.
Case Presentation
The patient was a 45-year-old male with a past medical his-
tory of intermittent asthma, hypertension, and type 2 diabe-
tes mellitus who presented to the emergency department 
(ED) via ambulance status post fall in the context of phency-
clidine (PCP) intoxication. Initially in the ED the patient was 
urinating on the floor, attempting to fight staff members, and 
uncooperative with examination. Intravenous haloperidol 5 
mg and midazolam 4 mg were administered for agitation, 
after which the patient was able to tolerate medical evalua-
tion and management. Additional history was limited at this 
time given the patient’s intoxicated state. The patient was 
unable to participate in a formal review of systems given his 
altered mental status (AMS). Initial vital signs were blood 
pressure 146/83 mm Hg, pulse 104 beats per minute, tem-
perature 98.4 °F, respiratory rate 18 breath per minute, and 
oxygen saturation 98%. Physical examination was grossly 
normal aside from a 3 cm stellate forehead laceration. Apart 
from a leukocytosis of 15 K/mm3, complete blood count, and 
comprehensive metabolic panel were within normal limits. 
Pertinent normal laboratory test results included a sodium of 
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Abstract
In this report, we describe a case of atypical neuroleptic malignant syndrome (NMS) presenting with an isolated lesion in 
the splenium of the corpus callosum (ILSCC). There is a paucity of information regarding this topic within the literature and 
only 7 previous case reports have been published at the time of writing. To our knowledge, this case report is also the first 
to describe an atypical NMS variant in the context of an ILSCC. In this report, we describe the important considerations 
in formulating differential diagnosis for ILSCC and are the first report to propose a possible pathophysiological mechanism 
relating ILSCC with NMS.
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140 mmol/L, blood urea nitrogen of 15, and a creatinine of 
0.87 mg/dL. Urine drug screen was positive for benzodiaze-
pines and PCP. Urinalysis was positive for only bacteria and 
nitrites along with 6 to 9 epithelial cells per high-power field 
suggesting possible contamination. Urine cultures were not 
obtained. Computerized tomography (CT) imaging demon-
strated left zygomaticomaxillary complex fractures without 
acute intracranial pathology. CT imaging of the patient’s cer-
vical spine did not demonstrate any acute pathology. While 
in the ED, the patient’s forehead laceration was sutured. The 
patient was admitted to an inpatient medicine unit for further 
management of his AMS and facial fracture.
On admission, the patient was somnolent, oriented only to 
self, and unable to engage with the admission assessment. An 
extensive AMS workup was completed, which included 
ammonia, vitamin B12 and folate levels, thyroid-stimulating 
hormone, blood cultures, C-reactive protein, repeat compre-
hensive metabolic panel/complete blood count, syphilis 
screen, and repeat head CT. Aside from a mildly elevated 
C-reactive protein of 2.6 mg/dL and leukocytosis of 14.2 K/
mm3 the remainder of the patient’s laboratory test results was 
within normal limits. Specific laboratory tests of interest 
pertinent to a delirium workup returned within normal limits 
as follows: ammonia 15 µmol/L, thyroid-stimulating hor-
mone 0.4, vitamin B12 576 pg/mL, and folate 22.9 ng/mL. 
The differential diagnosis for the patient’s AMS remained 
wide, so he was placed on the Clinical Institute Withdrawal 
Assessment for Alcohol protocol and started on intravenous 
thiamine as a history of alcohol use could not be ruled out. 
The patient was also given a 3-day course of intravenous cef-
triaxone considering equivocal urinalysis findings. Plastic 
surgery was consulted and recommended nonemergent elec-
tive repair of the facial fractures, but treatment was deferred 
as the patient remained altered and could not consent to the 
procedure.
Per family collateral, the patient worked part-time as a 
mechanic, lived alone, performed all activities of daily living 
independently, and did not have any history of neurologic or 
psychiatric disease. Family was unable to provide any addi-
tional information regarding the patient’s substance use. The 
patient did not receive any additional lorazepam per Clinical 
Institute Withdrawal Assessment for Alcohol protocol or for 
vital sign abnormalities consistent with alcohol withdrawal. 
Aside from his tachycardia on initial presentation in the ED, 
Figure 1. Images A, C, and E represent DWI, FLAIR, and ADC results, respectively, on initial imaging. Images B, D, and F represent 
DWI, FLAIR, and ADC results, respectively, 11 days after initial imaging. FLAIR, fluid-attenuated inversion recovery; DWI, diffusion-
weighted imaging; ADC, apparent diffusion coefficient.
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the patient did not demonstrate tachycardia after admission to 
the inpatient medicine unit. On the third hospital day, the 
patient’s AMS persisted, and neurology was consulted and 
evaluated the patient for additional causes of encephalopathy.
On the consulting neurologist’s initial examination, the 
patient remained lethargic, oriented only to self, unable to 
follow complex commands, and hypophonic with increased 
speech latency. No focal cranial nerve deficit was appreci-
ated; however, the patient exhibited hypertonicity with sig-
nificant oppositional paratonias in all 4 extremities along 
with bilaterally upgoing plantar reflexes. Magnetic reso-
nance imaging (MRI) and electroencephalography (EEG) 
were ordered per neurology recommendations. EEG did not 
demonstrate epileptiform activity or generalized slowing. 
However, MRI revealed a restricted diffusion/focal hyperin-
tensity within the splenium of the corpus callosum on diffu-
sion-weighted imaging (DWI) and fluid-attenuated inversion 
recovery (FLAIR) images, respectively. MRI findings on 
FLAIR, DWI, and ADC (apparent diffusion coefficient) are 
highlighted in Figure 1. In consideration of the patient’s 
recent exposure to neuroleptics, persistent encephalopathy, 
and significant oppositional paratonias, the possibility of an 
atypical variant of NMS contributing to the patient’s delir-
ium was likely. Despite the likelihood of atypical NMS, in 
considering the wide differential diagnosis of callosal lesions 
the probability of the MRI lesion representing a new infarct 
remained. Therefore, the patient was placed on standing 
aspirin 325 mg along with atorvastatin 40 mg daily. CT angi-
ography of the head and neck was completed and was unre-
markable. The patient was also started on standing 
benztropine 1 mg twice daily for atypical NMS. Of note, 
lorazepam was not used as there was concern for additional 
central nervous system depression in an already somnolent 
and delirious patient.
By the seventh hospital day, the patient became more 
alert, had improved orientation, was able to complete 2 step 
commands with prompting, and had reduced cogwheeling on 
examination. Additionally, the patient’s leukocytosis had 
down-trended to 13.2 K/mm3. The scheduled benztropine 
was also discontinued. The patient did not require any physi-
cal restraints or tranquilizers for agitation after admission. 
The patient’s MRI was repeated 11 days after initial imaging, 
which redemonstrated the corpus callosum splenium hyper-
intensity on FLAIR imaging and without restricted diffusion 
on DWI. The patient was instructed to repeat imaging as an 
outpatient to confirm the diagnosis of subacute callosal 
infarct versus transient splenial lesion of another etiology. 
The patient was recommended to be discharged to a rehabili-
tation facility to further manage his physical deconditioning 
and was subsequently lost to follow-up.
Discussion
At the time of writing, this is only the eighth documented case 
demonstrating concurrent ILSCC and NMS pathology.7-13 
NMS has phenotypic heterogeneity and should be viewed on 
a disease spectrum rather than as a discrete syndrome.3 Fever 
and autonomic instability are usually late findings in NMS, 
which can make identifying early presentations of NMS espe-
cially challenging.14 Consequently, a common disease variant 
lacking core malignant features has been conceptualized in 
the literature as atypical NMS.5 However, there is consider-
able uncertainty whether atypical NMS represents a distinct 
pathology or a prodromal phase destined to evolve with 
malignant features. Some authors have even proposed a 
multi-staged disease model of NMS in order to better account 
for atypical presentations.4 Of note NMS is a clinical diagno-
sis and specific laboratory or imaging results are not required 
to confer a diagnosis.15 For instance, our patient’s EEG was 
without epileptiform activity or generalized slowing, but pos-
itive EEG findings are not required to diagnose NMS or delir-
ium. In fact, a recent review suggested EEG testing may have 
a false positive and false negative rate as high as 20% when 
evaluating delirium.16 Therefore, despite being afebrile dur-
ing this hospitalization, the diagnosis of atypical NMS can 
still be rendered in our patient considering significant opposi-
tional paratonias and altered mental status in the context of 
recent neuroleptic exposure. Given our patients atypical NMS 
variant, an intensive care unit level of treatment including 
dantrolene was not required, especially in the absence of 
malignant features. Also, while benztropine is not a common 
therapeutic in the armamentarium for NMS care, mechanisti-
cally it functions similarly to alternative treatments like 
amantadine and bromocriptine. A core pathway within NMS 
pathophysiology is a depletion of basal ganglia dopaminergic 
neurotransmission secondary to neuroleptic exposure.17 
Dopaminergic drugs like amantadine and bromocriptine can 
be used to target this aberrant neurotransmission; however, in 
addition to its anticholinergic properties benztropine can also 
promote dopamine neurotransmission, making it a reasonable 
therapeutic in cases of atypical NMS.18
There remains some diagnostic uncertainty regarding the 
precise etiology of our patient’s ILSCC. A wide differential 
diagnosis exists for splenial lesions, which we have outlined 
in Table 1.19,20 For our patient, the differential included the 
following: ischemic lesion, oncologic lesion, traumatic lesion, 
transient splenial lesion secondary to NMS, and Marchiafava-
Bignami disease. With regard to ischemic etiologies, callosal 
infarcts are rare and unlikely to be isolated, as in our patient, 
due to a rich vascular supply emanating from both the anterior 
and posterior circulations.21,22 Additionally, our patient had an 
unremarkable CT angiogram of the head/neck, is young, did 
not have a history of infarct associated drug use, and was 
without a previous history of atrial fibrillation or stroke, mak-
ing an infarct less likely. Similarly, the possibility of an onco-
logic cause is unlikely given our patient did not have any 
systemic symptoms of cancer, did not have a family history, 
did not have a chronic prodrome of symptoms, and did not 
have imaging findings consistent with a space occupying 
lesion. It is feasible that our patient’s lesion was traumatic in 
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origin considering his head injury prior to arrival and the high 
axonal density within the corpus callosum predisposing it to 
shearing forces.19 However, axonal injury is rarely found in 
spatial isolation and would likely have a diffuse distribution 
given the severity of our patient’s injury as evident by the 
extent of his facial fractures.23 The probability of Marchiafava-
Bignami disease is doubtful given our patient did not have a 
history of alcohol abuse, had normal vitamin B12 and folate 
levels, had unremarkable liver function tests, and received 
prophylactic intravenous thiamine on admission.
Within previously published case reports documenting 
ILSCC in the context of NMS, the MRI lesion was character-
ized as midline symmetric ovoid, which matches the distinct 
morphology of our patient’s lesion.19 Prior reports have 
shown a complete resolution of the MRI lesion within 2 to 12 
weeks.7-13 In this case, imaging at 11 days showed a persis-
tent lesion. Consequently, it remains possible that if reim-
aged later on, our patient’s lesion may have been found to be 
transient as in the previously documented cases. Therefore, 
the possibility of an NMS associated lesion seemed plausible 
given our patients unique clinical picture without other com-
pelling etiologies. Despite being first described over a decade 
ago by Al-Edrus and colleagues,8 the pathophysiology of 
ILSCC associated with NMS remains elusive, and none of 
the existing case reports postulate an explanation.7,9-13 
Further exploration of the mechanistic underpinnings of 
ILSCC related to NMS may have utility in developing a 
more thorough understanding NMS pathophysiology, which 
might have diagnostic and treatment implications.
Despite the dearth of pathophysiologic postulates explain-
ing the relationship between ILSCC and NMS within psychi-
atric publications, it is possible to synthesize a possible 
mechanism from existing findings within the basic science 
literature. Transient callosal cytotoxic edema has been exten-
sively reviewed by Starkey and colleagues24 and defined as a 
common etiology of ILSCC. They suggest a cytokine-medi-
ated glutamate-induced N-methyl-D-aspartate receptor 
(NMDAR) excitotoxic process is central to the pathophysiol-
ogy of cytotoxic edema within the corpus callosum.24 With 
regard to NMS, Zhuravliova and colleagues25 demonstrated 
that haloperidol interactions with NMDAR resulted in gluta-
mate-independent cytochrome-C-dependent cytotoxicity. 
This is especially pertinent to ILSCC as there is a higher den-
sity of callosal Aquaporin-4 channels, relative to other brain 
regions, which are involved in cytochrome-C mediated cyto-
toxic pathways leading to localized edema.26,27 Additionally, 
PCP has been shown to cause upregulation of central 
NMDARs, which may have theoretically predisposed our 
patient to an NMS associated ILSCC.28 This proposed mech-
anism may be sufficient to explain the pathophysiology of 
these localized lesions in the context of NMS; however, 
additional case reports and confirmatory research are neces-
sary. Additionally, it is unclear if other antipsychotics men-
tioned in the previous case reports (risperidone, olanzapine, 
clozapine, and quetiapine) have similar contributions to the 
disease mechanism as haloperidol.
Conclusion
We have presented the first published case of an ILSCC 
in the context of atypical NMS, outlined the differential 
diagnosis for this rare finding, and postulated a neuro-
biological mechanism of disease. Given the widespread 
use of neuroleptics and availability of MRI, it is likely 
there are identified but unreported occurrences of these 
lesions. Conversely, a greater number of patients pre-
senting with a NMS-associated ILSCC without imaging 
unbeknown to their clinicians is also possible. Regardless, 
discussions of ILSCC and NMS expand the intellectual 
scaffold for a richer understanding of antipsychotics, 
NMS, clinical neuroscience, and potentially medical 
decision making.
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Table 1. Reported Etiologies of Splenial Lesions Adapted From Park et al19 and Uchino et al20.
Diagnostic category Specific etiologies
Traumatic Diffuse axonal injury, hemorrhage
Oncologic Lipoma, lymphoma, glioma, germinoma, metastasis
Vascular Infarction, hypoxic/ischemic encephalopathy, posterior reversible encephalopathy syndrome, hemolytic uremic 
syndrome, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
Toxic/metabolic Hypoglycemic encephalopathy, carbon monoxide intoxication, leukodystrophy
Degenerative/immune Multiple sclerosis, acute disseminated encephalomyelitis, Marchiafava-Bignami disease, Wallerian degeneration
Drug induced Metronidazole-induced encephalopathy, neuroleptic malignant syndrome, anti-epileptic withdrawal
Infectious Neonatal central nervous system viral infections, human immunodeficiency virus, tuberculosis, influenza
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Informed Consent
Informed consent for patient information to be published in this 
article was not obtained because of the patient’s altered mental sta-
tus. The patient’s age and other personal identifiers were anony-
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